These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1167308)

  • 21. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
    Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
    Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment.
    Shyu WC; Pittman KA; Wilber RB; Matzke GR; Barbhaiya RH
    J Clin Pharmacol; 1991 Apr; 31(4):362-71. PubMed ID: 2037710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
    Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
    J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacokinetics of ampicillin in patients with chronic renal insufficiency during hemodialysis and hemosorption].
    Iakovlev VP; Skala LZ; Cherniakov VL; Shcherbakov VA; Shuster AM
    Antibiot Med Biotekhnol; 1985 May; 30(5):380-3. PubMed ID: 4026260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metronidazole kinetics in dialysis patients.
    Kreeft JH; Ogilvie RI; Dufresne LR
    Surgery; 1983 Jan; 93(1 Pt 2):149-53. PubMed ID: 6849199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.
    Puttonen J; Kantele S; Kivikko M; Häkkinen S; Harjola VP; Koskinen P; Pentikäinen PJ
    Clin Pharmacokinet; 2007; 46(3):235-46. PubMed ID: 17328582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure.
    Desager JP; Costermans J; Verberckmoes R; Harvengt C
    Nephron; 1982; 31(1):51-4. PubMed ID: 7110477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of ranitidine after intravenous administration in hemodialysis patients.
    Garg DC; Baltodano N; Perez GO; Oster JR; Jallad NS; Weidler DJ
    Pharmacology; 1985; 31(4):189-93. PubMed ID: 4059323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disposition of cefpodoxime proxetil in hemodialysis patients.
    Borin MT; Hughes GS; Kelloway JS; Shapiro BE; Halstenson CE
    J Clin Pharmacol; 1992 Nov; 32(11):1038-44. PubMed ID: 1474165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elimination of ioversol by hemodialysis.
    Ueda J; Furukawa T; Takahashi S; Sakaguchi K
    Acta Radiol; 1996 Sep; 37(5):826-9. PubMed ID: 8915301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of cefepime in subjects with renal insufficiency.
    Barbhaiya RH; Knupp CA; Forgue ST; Matzke GR; Guay DR; Pittman KA
    Clin Pharmacol Ther; 1990 Sep; 48(3):268-76. PubMed ID: 2401125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-finding study of rivaroxaban in hemodialysis patients.
    De Vriese AS; Caluwé R; Bailleul E; De Bacquer D; Borrey D; Van Vlem B; Vandecasteele SJ; Emmerechts J
    Am J Kidney Dis; 2015 Jul; 66(1):91-8. PubMed ID: 25804678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Removal of uremic retention products by hemodialysis is coupled with indiscriminate loss of vital metabolites.
    Zhang ZH; Mao JR; Chen H; Su W; Zhang Y; Zhang L; Chen DQ; Zhao YY; Vaziri ND
    Clin Biochem; 2017 Dec; 50(18):1078-1086. PubMed ID: 28928007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of rilmenidine in patients with chronic renal insufficiency and in hemodialysis patients.
    Aparicio M; Dratwa M; el Esper N; Fillastre JP; Levaltier B; Lins R; Meyrier A; Mignon F; Ryckelynck JP; Sennesael J
    Am J Cardiol; 1994 Dec; 74(13):43A-50A. PubMed ID: 7998585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of propranolol, practolol and metoprolol on exercise-induced tachycardia in relation to plasma levels in man.
    Williams FM; Singh BN; Ambler PK; Dorrington R
    Clin Exp Pharmacol Physiol; 1976; 3(5):473-82. PubMed ID: 975632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis.
    Evans AM; Faull R; Fornasini G; Lemanowicz EF; Longo A; Pace S; Nation RL
    Clin Pharmacol Ther; 2000 Sep; 68(3):238-49. PubMed ID: 11014405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis.
    Mistry GC; Majumdar AK; Swan S; Sica D; Fisher A; Xu Y; Hesney M; Xi L; Wagner JA; Deutsch PJ
    J Clin Pharmacol; 2006 Oct; 46(10):1128-38. PubMed ID: 16988201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of practolol in the rabbit with experimental glomerulonephritis.
    Harvengt C; Desager JP; Vanderbist M
    Pharmacology; 1975; 13(6):533-8. PubMed ID: 1221435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of netilmicin in renal insufficiency and hemodialysis.
    Herrero A; Rius Alarcó F; García Díez JM; Mahiques E; Domingo JV
    Int J Clin Pharmacol Ther Toxicol; 1988 Feb; 26(2):84-7. PubMed ID: 3045024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure.
    MacPhee IA; Spreafico S; Bewick M; Davis C; Eastwood JB; Johnston A; Lee T; Holt DW
    Kidney Int; 2000 Mar; 57(3):1164-8. PubMed ID: 10720968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.